Back to Results
First PageMeta Content



WELLINGTON PARTNERS SELLS ITS SHARES IN DEFINIENS TO MEDIMMUNE   MedImmune strengthens immuno-oncology capabilities with acquisition of Definiens for an initial consideration of $150 million
Add to Reading List

Document Date: 2015-05-04 11:17:32

Open Document

File Size: 97,37 KB

Share Result on Facebook

City

Zurich / Munich / London / /

Company

Genticel / Implanet / Novartis / Evolva / Quanta / Symetis / MPM Medical / Sullivan Company / MTM Laboratories / Sensimed / Alcon / Noemalife / Sapiens / Wellington Partners IV Life Science Fund / Global Tissue Diagnostics / Roche / pan-European Venture Capital / Supersonic Imagine / Wellington Partners Wellington Partners / MEDIMMUNE / Actelion / Oxagen / Xing / Wavelight / Deutsche Telekom / ImmobilienScout24 / NEUWAY Pharma / Grandis / AyoxxA / AstraZeneca / Oxford Immunotec / DEFINIENS / Spotify / /

Continent

Europe / /

Currency

USD / EUR / /

/

Event

M&A / /

Facility

AstraZeneca’s pipeline / /

IndustryTerm

personalised healthcare approach / data analysis technology / imaging / important tool / digital media / data mining solutions / /

MedicalCondition

cancer / tumour / /

Organization

Life Science Fund / /

Person

Bahija Jallal / Rainer Strohmenger / Gerd Binnig / Thomas Heydler / /

/

Position

General Partner / Chief Executive Officer / Professor / Executive Vice President / /

Technology

genomics / data analysis technology / data mining / /

URL

www.definiens.com / www.wellington-partners.com / /